Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Erik J M van Bommel; Yuliya Lytvyn; Bruce A Perkins; Nima Soleymanlou; Nora M Fagan; Audrey Koitka-Weber; Jaap A Joles; David Z I Cherney; Daniël H van Raalte

doi:10.1016/j.kint.2019.12.021

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Erik J M van Bommel, Yuliya Lytvyn, Bruce A Perkins, Nima Soleymanlou, Nora M Fagan, Audrey Koitka-Weber, Jaap A Joles, David Z I Cherney, Daniël H van Raalte

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	631-635
Number of pages	5
Journal	Kidney International
Volume	97
Issue number	4
DOIs	https://doi.org/10.1016/j.kint.2019.12.021
Publication status	Published - Apr 2020

Keywords

SGLT2 inhibition
diabetes
diabetic nephropathy
glomerular hyperfiltration

Access to Document

10.1016/j.kint.2019.12.021

Cite this

van Bommel, E. J. M., Lytvyn, Y., Perkins, B. A., Soleymanlou, N., Fagan, N. M., Koitka-Weber, A., Joles, J. A., Cherney, D. Z. I., & van Raalte, D. H. (2020). Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function. Kidney International, 97(4), 631-635. https://doi.org/10.1016/j.kint.2019.12.021

@article{5e0b02a0495247bfbf3dd045e75f1b24,

title = "Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function",

keywords = "SGLT2 inhibition, diabetes, diabetic nephropathy, glomerular hyperfiltration",

author = "{van Bommel}, {Erik J M} and Yuliya Lytvyn and Perkins, {Bruce A} and Nima Soleymanlou and Fagan, {Nora M} and Audrey Koitka-Weber and Joles, {Jaap A} and Cherney, {David Z I} and {van Raalte}, {Dani{\"e}l H}",

note = "Funding Information: The Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (RED) trial (NCT02682563) in people with T2D was funded by AstraZeneca and the Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With and Without Renal Hyperfiltration (ATIRMA) trial (NCT01392560) in people with T1D by Boehringer Ingelheim . Editorial and graphical support, supported financially by Boehringer Ingelheim, was provided by Andy Shepherd of Elevate Scientific Solutions. ",

year = "2020",

month = apr,

doi = "10.1016/j.kint.2019.12.021",

language = "English",

volume = "97",

pages = "631--635",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier",

number = "4",

}

van Bommel, EJM, Lytvyn, Y, Perkins, BA, Soleymanlou, N, Fagan, NM, Koitka-Weber, A, Joles, JA, Cherney, DZI & van Raalte, DH 2020, 'Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function', Kidney International, vol. 97, no. 4, pp. 631-635. https://doi.org/10.1016/j.kint.2019.12.021

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function. / van Bommel, Erik J M; Lytvyn, Yuliya; Perkins, Bruce A et al.
In: Kidney International, Vol. 97, No. 4, 04.2020, p. 631-635.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

AU - van Bommel, Erik J M

AU - Lytvyn, Yuliya

AU - Perkins, Bruce A

AU - Soleymanlou, Nima

AU - Fagan, Nora M

AU - Koitka-Weber, Audrey

AU - Joles, Jaap A

AU - Cherney, David Z I

AU - van Raalte, Daniël H

N1 - Funding Information: The Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (RED) trial (NCT02682563) in people with T2D was funded by AstraZeneca and the Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With and Without Renal Hyperfiltration (ATIRMA) trial (NCT01392560) in people with T1D by Boehringer Ingelheim . Editorial and graphical support, supported financially by Boehringer Ingelheim, was provided by Andy Shepherd of Elevate Scientific Solutions.

PY - 2020/4

Y1 - 2020/4

KW - SGLT2 inhibition

KW - diabetes

KW - diabetic nephropathy

KW - glomerular hyperfiltration

UR - http://www.scopus.com/inward/record.url?scp=85081202146&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2019.12.021

DO - 10.1016/j.kint.2019.12.021

M3 - Editorial

C2 - 32200854

SN - 0085-2538

VL - 97

SP - 631

EP - 635

JO - Kidney International

JF - Kidney International

IS - 4

ER -

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Keywords

Access to Document

Other files and links

Cite this